Curetis has raised $16.3 million in Series B financing, which it will use to support its operational and commercial expansion. The Germany-based firm plans to submit an FDA 510(k) clearance application next year for its Unyvero system, a DNA-based diagnostics platform that can detect multiple antibiotic-resistant organisms and bacteria from a single sample in one go.
German molecular Dx company obtains $16.3M in financing
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|